ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2771

PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica

Niklas Thomas Baerlecken1, Torsten Witte2, Marco Amedeo Cimmino3 and Dario Camellino4, 1Clinical Immunology and Rheumatology, MD, Hannover, Germany, 2Medical School Hannover, MD, Hanover, Germany, 3Clinica Reumatologica, Università di Genova, Genova, Italy, 4Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antibodies, polymyalgia rheumatica and positron emission tomography (PET)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Previously we described antibodies against ferritin heavy chain peptide (anti-FHCP) in sera of patients with giant cell arteritis (GCA) and/or polymyalgia rheumatic (PMR) before glucocorticoid treatment was initiated. In that study, it remained unclear however, whether the PMR patients may have suffered from additional undiagnosed GCA. Therefore, we now measured antibodies against FHCP in PMR patients in whom GCA had been excluded by FDG-PET scan.

Methods

Sera of 63 patients were studied that presented initially with symptoms of PMR. A PET-CT had been performed in all patients and revealed large vessel vasculitis in 27 of these patients (GCA/PMR), whereas 36 had no signs of vasculitis (PMR). In a single-blinded study, we measured anti-FHCP in these patients and in a control group of patients with rheumatic diseases (RD, n=26), malignant diseases (MD, n=15) and infectious febrile diseases (IFD, n=22).

In the ELISA 3 peptides of the ferritin heavy chain were used as antigens: A19-45 (AAINRQINLELYASYVYLSMSYYFDRF), A79-104 (GRIFQDIKKPCDDWESGLNAMECA) and A105-143 (LHEKNVNQSLELHKLATDKNDPHLCFIETHYLNEQVK). 

Results

The frequency of antibodies against A19-45 were 38/63 (60%) in all PMR patients and 14/63 (22%) in controls (p<0.0001), of antibodies against A79-104 30/63 (48%) in all PMR patients and 9/63 (14%) in controls (p=0.0001) and of antibodies against A105-143 38/63 (60%) in PMR and 12/63 (19%) in controls (p<0.0001). There were no differences within the controls considering all antigens.

Comparing the patients with and without vascular involvement in PET-CT, the frequencies of antibodies against A19-45 (18/27 (67%) and 20/36 (56%), (p=0.53)), against A79-104 (14/27 (52%) and 16/36 (44%) (p=0.74)) and against A105-143 (19/27 (70%) and 19/36 (53%) (p=0.25)) were not different. 

Conclusion

This single-blinded study confirms the frequency of anti-FHCP in a different cohort. Anti-FHCP are associated with both GCA/PMR and PMR only.


Disclosure:

N. T. Baerlecken,
None;

T. Witte,
None;

M. A. Cimmino,
None;

D. Camellino,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pet-ct-imaging-and-association-of-ferritin-autoantibodies-in-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology